“Ampyra’s been part of my way of continuing to walk and live my life.” -Lisa

What Happens When a Loved One Starts Taking AMPYRA?

AMPYRA may help them improve their walking

AMPYRA® (dalfampridine) is the only FDA-approved medication shown to improve walking in people with multiple sclerosis (MS). AMPYRA improved walking in significantly more people than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%). Improving walking may help with even the simplest things, like keeping up with friends and family. Not everyone responds to AMPYRA. Individual results may vary.

In the clinical studies, people who walked faster, regardless of treatment, also reported improvements in their walking-related activities* using the 12-item Multiple Sclerosis Walking Scale (or MSWS-12).

*A drug/placebo difference was not established for this outcome measure.

How soon might they notice a change in how they walk?

Some people experience improvement in their walking ability within a couple of weeks. Others notice improvement up to 6 weeks after starting.

Not everyone responds to AMPYRA. Individual results may vary. It’s important to take AMPYRA as prescribed by your doctor.

Can AMPYRA cause side effects?

AMPYRA may cause seizures, even in people who have never had a seizure before. The chance of having a seizure is higher in people who take too much AMPYRA or in people whose kidneys have a mild decrease of function, which is common after age 50.

AMPYRA may cause serious side effects, including kidney or bladder infections, and serious allergic reactions. Anyone taking AMPYRA should stop and call the doctor right away or get emergency medical help if they have shortness of breath or trouble breathing, swelling of the throat or tongue, or hives. The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.

For more information, please see the complete Medication Guide.

AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

IMPORTANT NEW SAFETY INFORMATION

Do not take AMPYRA if you are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

IMPORTANT SAFETY INFORMATION

Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.

Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.

AMPYRA may cause serious allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.

Before taking AMPYRA tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.

Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.

Please see the full Prescribing Information and Patient Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc. | AMPYRA® is marketed by Acorda Therapeutics®, Inc. and manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland | AMPYRACONNECT™ is a trademark of Acorda Therapeutics®, Inc. | The stylized path logo is a trademark of Acorda Therapeutics®, Inc. | The stylized Acorda logo is a trademark of Acorda Therapeutics®, Inc. | © 2013 Acorda Therapeutics®, Inc. All rights reserved.

AMP2043